six
seri
semisynthet
lipophil
glycopeptid
antibiot
deriv
evalu
vitro
activ
influenza
b
virus
new
teicoplanin
pseudoaglyconderiv
lipoglycopeptid
prepar
coupl
one
two
side
chain
nterminu
glycopeptid
core
use
variou
conjug
method
three
seri
deriv
bear
two
lipophil
group
synthes
attach
bisalkylthio
maleimid
directli
linker
differ
length
glycopeptid
access
fourth
fifth
seri
compound
achiev
click
chemistri
introduc
singl
alkylaryl
chain
directli
tetraethylen
glycol
linker
posit
sixth
group
semisynthet
deriv
obtain
sulfonyl
nterminu
lipophil
teicoplanin
pseudoaglycon
deriv
test
half
show
broad
activ
influenza
b
virus
reason
cytotox
minor
differ
side
chain
length
well
lipophil
appear
signific
impact
antivir
activ
cytotox
sever
lipoglycopeptid
also
found
activ
human
coronaviru
human
influenza
b
virus
caus
annual
influenza
epidem
sporad
pandem
associ
high
fatal
rate
viral
envelop
contain
two
glycoprotein
crucial
role
viru
replic
hemagglutinin
ha
respons
initi
attach
viru
sialyl
cell
surfac
glycan
fusion
viral
endosom
membran
endocytosi
viru
particl
influenza
viru
neuraminidas
na
catalyz
releas
newli
form
virion
end
viral
life
cycl
current
avail
influenza
viru
blocker
na
inhibitor
oseltamivir
zanamivir
ion
channel
blocker
amantadin
rimantadin
latter
two
rare
use
nowaday
global
viral
resist
increas
awar
potenti
oseltamivir
resist
advoc
need
new
antiinfluenza
medic
clinic
trial
ongo
hatarget
approach
ie
fusion
inhibitor
arbidol
divers
broadli
neutral
antiha
antibodi
addit
possibl
target
host
factor
involv
ha
function
test
ha
matur
inhibitor
nitazoxanid
receptordestroy
sialidas
enzym
besid
variou
concept
preclin
stage
antivir
drug
also
requir
pandem
prepared
zoonot
highli
virul
influenza
virus
context
antivir
glycopeptid
analogu
seem
particularli
abbrevi
dcm
dichloromethan
dmf
dimethylformamid
cpe
cytopath
effect
et
n
triethylamin
galp
galactopyranos
ha
hemagglutinin
hiv
human
immunodefici
viru
logp
logarithm
partit
coeffici
mcc
minimum
cytotox
concentr
mdck
canin
kidney
mt
na
neuraminidas
ph
phenyl
pmb
pmethoxybenzyl
sarscov
sever
acut
respiratori
syndrom
coronaviru
si
select
index
sem
standard
error
mean
teg
tetraethylen
glycol
tlc
thin
layer
chromatographi
tosyl
ptoluenesulfonyl
relev
sinc
often
display
broad
activ
influenza
plu
emerg
virus
deriv
teicoplanin
relat
antibiot
report
inhibit
among
other
influenza
viru
coronavirus
includ
sarscov
sever
acut
respiratori
syndrom
coronaviru
ebola
pseudoviru
hiv
hepat
c
viru
focu
last
year
investig
structureact
relationship
mechan
action
influenza
viru
report
lipophil
deriv
ristocetin
aglycon
modifi
ntermin
part
molecul
prove
strong
inhibitor
influenza
viru
replic
cell
cultur
mechanist
studi
lead
compound
demonstr
interfer
influenza
viru
endocytosi
favor
select
index
encourag
us
prepar
seri
analogu
gain
insight
structur
activ
relationship
outstand
antivir
properti
lost
analogu
contain
teicoplanin
aglycon
pseudoaglycon
mean
minor
structur
differ
aglycon
teicoplanin
ristocetin
major
impact
antivir
activ
next
found
special
lipophil
modif
teicoplanin
pseudoaglycon
also
result
deriv
high
antiinfluenza
viru
activ
deriv
contain
sugar
unit
carri
two
noctyl
chain
lipophil
auxiliari
attach
teicoplanin
pseudoaglycon
tetraethylen
glycol
chain
triazol
ring
fig
although
antivir
mode
action
remain
elucid
observ
dualli
octyl
teicoplanin
pseudoaglycon
deriv
inhibit
influenza
virusinduc
hemagglutin
suggest
interfer
bind
interact
viral
ha
sialyl
host
cell
receptor
also
found
lipophil
side
chain
molecul
essenti
antiinfluenza
viru
activ
sinc
chang
octyl
chain
methyl
group
complet
abolish
antivir
effect
unfortun
strong
activ
accompani
high
cytotox
inact
less
amphiphil
moder
toxic
surprisingli
recent
found
teicoplanin
pseudoaglycon
achiev
antiinfluenza
viru
properti
simpl
lipophil
modif
base
wellknown
azidealkyn
cycloaddit
click
reaction
activ
oddli
correl
structur
sinc
disappear
reappear
increas
length
lipophil
alkyl
chain
chang
cytotox
howev
consist
indic
addit
longer
alkyl
substitu
result
higher
cytotox
although
compound
show
excel
inhibitori
activ
influenza
viru
select
indic
unfavor
noteworthi
deriv
amphiphil
bulki
substitu
display
antiinfluenza
viru
activ
without
signific
cytotox
despit
high
calcul
logp
valu
aim
achiev
deriv
favor
biolog
properti
decid
carri
systemat
structureact
relationship
analysi
teicoplanin
pseudoaglycon
deriv
resembl
eg
simpl
conjug
method
protein
peptid
modif
report
involv
rapid
clean
reaction
thiol
give
bisalkylthio
maleimid
high
yield
additionelimin
mechan
envis
applic
maleimid
chemistri
combin
azidealkyn
fig
structur
previous
synthes
teicoplanin
deriv
compound
show
promis
antiinfluenza
viru
activ
inact
show
modest
activ
click
chemistri
produc
three
set
teicoplanin
deriv
equip
two
lipophil
substitu
similarli
discuss
deriv
denot
seri
compound
refer
sar
analysi
seri
two
set
deriv
seri
compar
contain
one
lipophil
alkyl
chain
prepar
azidealkyn
cycloaddit
reaction
nsulfonyl
describ
synthesi
antivir
investig
compound
chemistri
first
group
deriv
prepar
synthes
variou
bisalkylthio
maleimid
follow
subsequ
ethoxycarbonyl
maleimid
nh
group
make
compound
suitabl
conjug
nterminu
teicoplanin
pseudoaglycon
scheme
although
describ
path
earlier
synthesi
compound
time
also
prepar
bisnbutylthio
bisnhexylthio
maleimid
deriv
sake
systemat
approach
studi
also
prepar
asymmetr
substitut
maleimid
variant
npropyl
ndodecyl
function
second
seri
deriv
contain
similar
maleimidederiv
side
chain
previou
group
attach
triazol
linker
glycopeptid
core
order
increas
distanc
lipophil
chain
pseudoaglycon
synthet
procedur
prepar
npropargyl
maleimid
reaction
correspond
nethoxycarbonyl
maleimid
propargylamin
final
azidealkyn
click
reaction
carri
azido
teicoplanin
pseudoaglycon
maleimid
yield
final
product
scheme
third
group
deriv
carri
maleimid
substitu
differ
previou
one
structur
linker
case
contain
tetraethylen
glycol
segment
besid
triazol
ring
compound
introduct
tetraethylen
glycol
fragment
overal
lipophil
compound
reduc
crucial
lipophil
substitu
still
incorpor
structur
linker
modif
prove
substanti
effect
biolog
profil
molecul
see
compound
suitabl
type
modif
prepar
simpl
reaction
nethoxycarbonyl
scheme
synthesi
maleimid
deriv
seri
doubl
lipophil
tail
direct
coupl
teicoplanin
pseudoaglycon
scheme
conjug
bisalkylthio
maleimid
deriv
azido
teicoplanin
pseudoaglycon
triazol
moieti
seri
maleimid
triethylen
glycol
propargyl
ether
subsequ
click
reaction
azido
teicoplanin
pseudoaglycon
gave
glycopeptid
scheme
fourth
type
modif
describ
base
previou
result
mention
although
compound
possess
singl
rel
long
alkyl
chain
highli
activ
influenza
viru
also
display
consider
cytotox
sake
clariti
compound
list
separ
seri
ie
seri
tabl
structur
found
fig
specul
high
cytotox
might
relat
combin
two
factor
first
high
lipophil
side
chain
contrast
hydrophil
pseudoaglycon
part
may
caus
membranedisrupt
effect
might
enhanc
simpl
structur
alkyl
chain
could
facilit
insert
molecul
biolog
membran
previou
work
attach
two
bulki
substitu
perbenzyl
disaccharid
calix
aren
carri
tertbutylsubstitu
pseudoaglycon
calcul
logp
valu
compound
indic
higher
lipophil
eg
nhexadecyl
noctyl
deriv
deriv
produc
profound
cytotox
effect
support
hypothesi
cytotox
determin
combin
lipophil
bulki
substitu
need
mention
compon
teicoplanin
dring
nacyl
similarli
simpl
acyl
chain
yet
compound
seem
harmless
mammalian
cell
therefor
overal
lipophil
molecul
may
also
influenc
cytotox
sinc
introduct
alkyl
chain
prove
promis
term
antivir
activ
decid
insert
tetraethylen
glycol
linker
core
substitu
order
decreas
lipophil
case
maleimid
deriv
caus
signific
chang
biolog
properti
first
monoazido
deriv
tetraethylen
glycol
util
click
reaction
alkyl
propargyl
ether
yield
triazol
deriv
oalkyl
propargyl
bromid
provid
compound
use
last
step
cuaac
reaction
azido
teicoplanin
pseudoaglycon
obtain
deriv
scheme
final
reaction
teicoplanin
pseudoaglycon
differ
sulfonyl
chlorid
prepar
sulfonamid
deriv
scheme
type
derivat
attract
mainli
simplic
high
stabil
sulfonamid
bond
despit
knowledg
one
thu
far
report
type
deriv
teicoplanin
relat
glycopeptid
biolog
evalu
antiinfluenza
viru
activ
determin
madindarbi
canin
kidney
mdck
cell
use
report
cytopath
effect
cpe
reduct
method
cpe
assess
microscopi
plu
formazanbas
cell
viabil
assay
parallel
cytotox
determin
mockinfect
cell
tabl
summar
data
three
human
influenza
strain
includ
pandem
strain
plu
one
influenza
b
strain
seri
maleimid
deriv
show
variabl
activ
four
influenza
viru
strain
test
neither
prove
potent
compound
compound
display
quit
consist
activ
four
strain
curious
enough
neither
doubl
npropyl
doubl
ndodecyl
substitut
maleimid
moieti
yield
activ
compound
combin
npropyl
ndodecyl
chain
compound
led
notabl
activ
fair
activ
compound
carri
doubl
galactos
substitut
maleimid
accompani
modest
select
si
select
index
si
ratio
mcc
averag
ec
indic
need
structur
modif
order
reduc
cytotox
seri
contain
triazol
linker
overal
success
influenza
viru
somewhat
lower
cytotox
first
seri
name
antivir
activ
seen
case
compound
contain
doubl
nbutyl
nhexyl
noctyl
chain
respect
presenc
linker
highli
alter
behavior
compound
sinc
analog
deriv
previou
seri
ie
triazol
linker
alkyl
chain
length
inact
display
robust
antivir
activ
favor
si
wherea
particular
still
poor
select
doubl
ndodecyl
moieti
remain
inact
becam
less
cytotox
gener
find
seri
sadli
doubl
galactos
substitut
deriv
lost
activ
introduct
triazol
linker
biolog
result
seri
demonstr
introduc
tetraethylen
glycol
linker
cytotox
gener
reduc
antiinfluenza
viru
activ
retain
nbutyl
nhexyl
deriv
even
increas
noctyl
analogu
sinc
tetraethylen
glycol
element
seem
benefici
also
prepar
deriv
doubl
tetraethylen
glycol
side
chain
modif
yield
activ
compound
probabl
miss
lipophil
moieti
prove
essenti
antiinfluenza
viru
activ
see
conclus
surprisingli
despit
lack
lipophil
moieti
compound
prove
highli
cytotox
ultim
stood
promis
compound
group
low
cytotox
robust
activ
test
strain
yield
nice
si
activ
triazol
deriv
seri
alreadi
publish
elsewher
data
shown
consid
systemat
approach
present
report
structur
analog
compound
work
surprisingli
among
alkyl
substitut
compound
nhexadecyl
noctyl
deriv
show
high
activ
attach
ndodecyl
ndecyl
side
chain
led
inact
compound
howev
four
deriv
high
cytotox
nhexyl
side
chain
compound
aromat
substitu
mildli
activ
scheme
conjug
bisalkylthio
maleimid
deriv
equip
ntegpropargyl
moieti
azido
teicoplanin
pseudoaglycon
gave
seri
c
cytotox
express
minimum
cytotox
concentr
mcc
compound
concentr
produc
minim
chang
cell
morpholog
estim
microscopi
cytotox
concentr
cc
estim
mt
cell
viabil
assay
data
repres
mean
two
five
independ
test
moder
cytotox
interestingli
perbenzyl
lactos
calix
aren
deriv
display
moder
high
activ
accompani
modest
cytotox
despit
high
calcul
logp
valu
indic
much
higher
lipophil
compar
state
explan
could
although
molecul
lipophil
bulki
structur
may
lead
inabl
disrupt
cellular
membran
case
alkyl
deriv
investig
tetraethylen
glycol
linker
impact
cytotox
synthes
seri
deriv
analog
alkyl
chaincontain
triazol
deriv
seri
specul
introduct
linker
would
boost
antivir
activ
reduc
cytotox
compar
publish
compound
inde
compound
analogu
show
excel
antivir
activ
reason
cytotox
compar
highli
cytotox
devoid
antiinfluenza
viru
activ
interestingli
lower
length
alkyl
chain
analogu
yield
effect
compound
also
sulfonamid
deriv
seri
size
type
lipophil
substitu
seem
play
import
role
less
hydrophob
tosyl
benzenesulfonyl
pacetamidobenzenesulfonyl
deriv
rather
low
antiinfluenza
viru
activ
also
cytotox
howev
lipophil
aryl
substitut
compound
biphenylsulfonyl
dansyl
deriv
display
good
activ
unfortun
also
cytotox
mdck
cell
relationship
alkyl
chain
length
cytotox
antivir
activ
clear
case
alkylsulfon
hexanesulfonyl
deriv
best
compound
show
moder
cytotox
consist
antiinfluenza
viru
activ
grow
alkyl
chain
length
activ
rapidli
increas
cytotox
inhibit
influenza
haand
nabear
lentivir
pseudoparticl
previous
publish
antiinfluenza
viru
mechan
action
lipophil
deriv
aglycoristocetin
denot
compound
prove
nice
activ
assay
green
fluoresc
protein
gfp
express
lentivir
pseudoparticl
bear
influenza
viru
ha
na
consist
find
interfer
hamedi
endocytosi
use
procedur
two
potent
teicoplanin
pseudoaglycon
deriv
strong
dosedepend
inhibit
seen
four
control
compound
fig
ie
chloroquin
inhibitor
endosom
acidif
two
anilinebas
influenza
fusion
inhibitor
fig
inhibit
conform
refold
ha
low
endosom
ph
inhibit
pseudoparticl
entri
deduc
reduct
gfp
signal
mm
mm
likewis
produc
reduct
mm
activ
human
coronaviru
given
teicoplanin
relat
glycopeptid
report
anticoronaviru
activ
evalu
subset
newli
synthes
compound
human
coronaviru
use
two
complementari
method
ie
cpe
reduct
human
embryon
lung
hel
fibroblast
cell
viru
yield
reduct
human
lung
carcinoma
cell
among
seri
test
analogu
carri
alkyl
group
intermedi
length
ie
nbutyl
nhexyl
seri
entir
seri
test
antivir
activ
valu
obtain
see
tabl
support
inform
hel
cell
show
nice
agreement
cell
sever
compound
produc
ie
reduct
coronaviru
yield
concentr
mm
minim
cytotox
mm
alkanesulfonamid
deriv
display
potent
anticoronaviru
activ
term
ec
mm
si
ratio
mcc
ec
within
seri
ptoluenesulfonamid
analogu
also
nice
activ
select
si
summari
synthes
evalu
sever
deriv
teicoplanin
pseudoaglycon
systemat
manner
obtain
structureact
relationship
concern
antiinfluenza
viru
activ
compound
mani
lipoglycopeptid
exhibit
remark
activ
influenza
b
virus
show
occasion
favor
select
index
base
biolog
data
becam
evid
inhibit
influenza
viru
replic
primarili
depend
type
complex
chemic
bond
function
group
glycopeptid
nterminu
newli
introduc
fragment
structur
side
chain
even
overal
lipophil
compound
influenti
biolog
properti
henc
presenc
lipophil
side
chain
definit
requir
antivir
activ
optim
length
alkyl
substitu
somewhat
depend
structur
linker
usual
equival
methylen
group
side
chain
carri
two
alkyl
group
reduc
length
might
enough
e
g
doubl
butyl
substitut
incorpor
longer
alkyl
group
carbon
atom
seri
might
also
lead
activ
compound
howev
prove
highli
cytotox
latter
even
note
compound
optimum
side
chain
length
eg
reduc
cytotox
preserv
antivir
activ
achiev
incorpor
tetraethylen
glycol
linker
case
modif
led
improv
deriv
becam
less
activ
probabl
due
loss
requir
lipophil
analyz
influenc
aryl
substitut
difficult
sinc
type
substitu
present
two
compound
seri
seri
smaller
number
nevertheless
analogu
seem
display
similar
relationship
lipophil
antiinfluenza
viru
activ
cytotox
alkyl
substitut
compound
compound
contain
one
aromat
ring
usual
activ
cytotox
two
aromat
ring
seem
boost
antivir
activ
increas
lipophil
cytotox
also
becom
promin
interestingli
two
compound
carri
numer
aromat
ring
form
highli
bulki
lipohydrophil
side
chain
effect
one
influenza
viru
strain
without
caus
seriou
cytotox
mention
earlier
like
cytotox
lipoglycopeptid
increas
compound
abil
solubil
cellular
membran
net
lipophil
bulki
amphiphil
side
chain
effect
might
weaker
compar
simpl
structur
alkyl
chain
could
easili
insert
lipid
membran
could
explain
appar
contradict
analogu
display
high
lipophil
without
sever
cytotox
evid
major
challeng
lie
design
optim
lipoglycopeptid
structur
provid
suffici
lipophil
antiinfluenza
viru
activ
without
caus
seriou
cytotox
demonstr
high
activ
goe
hand
hand
high
toxic
mani
instanc
still
studi
prove
activ
lead
compound
identifi
possibl
diminish
cytotox
appli
appropri
structur
adjust
besid
modif
describ
unlimit
variat
could
lead
deriv
excel
biolog
profil
moreov
seen
promis
antivir
activ
limit
influenza
viru
sinc
deriv
also
display
activ
human
coronaviru
make
class
lipoglycopeptid
relev
class
investig
compound
respect
propargylamin
alkyl
thiol
purchas
sigma
aldrich
chemic
co
dansyl
chlorid
benzenesulfonyl
chlorid
pacetamidobenzenesulfonyl
chlorid
biphenylsulfonyl
chlorid
purchas
tokyo
chemic
industri
co
ltd
alkyl
sulfonyl
chlorid
prepar
correspond
thiol
use
literatur
method
triethylen
glycol
propargyl
ether
teicoplanin
pseudoaglycon
azido
teicoplanin
pseudoaglycon
also
prepar
accord
literatur
procedur
tlc
analysi
perform
kieselgel
f
merck
silica
gel
plate
visual
immers
ammoniummolibd
solut
follow
heat
paulyreag
case
teicoplaninderiv
flash
column
chromatographi
perform
silica
gel
merck
mm
organ
solut
dri
na
concentr
vacuum
h
mhz
stir
solut
bisalkylthio
maleimid
equiv
dri
aceton
ml
k
co
equiv
ethyl
chloroform
equiv
ad
argon
atmospher
stir
h
room
temperatur
reaction
mixtur
dilut
ch
cl
filter
pad
celit
concentr
crude
product
use
step
without
purif
stir
solut
nethoxycarbonyl
bisalkylthio
maleimid
equiv
ch
cl
ml
propargylamin
triethylen
glycol
propargyl
ether
equiv
et
n
equiv
ad
argon
atmospher
stir
overnight
room
temperatur
reaction
mixtur
dilut
ch
cl
wash
cc
nh
cl
water
twice
dri
na
filter
concentr
crude
product
purifi
flash
chromatographi
give
desir
compound
stir
solut
azid
equiv
dri
dmf
ml
alkyn
compound
equiv
et
n
equiv
cu
mol
ad
argon
atmospher
stir
overnight
room
temperatur
reaction
mixtur
concentr
crude
product
purifi
flash
chromatographi
case
teicoplanin
deriv
toluenemethanol
vv
acet
acid
acetonitrilewat
mixtur
use
eluent
stir
suspens
nah
equiv
dri
dmf
ml
alcohol
equiv
ad
dropwis
c
min
alkylbromid
equiv
ad
dropwis
stir
h
reaction
mixtur
quench
methanol
concentr
dilut
dcm
wash
twice
water
dri
na
filter
concentr
crude
product
purifi
flash
chromatographi
give
desir
compound
stir
solut
teicoplanin
pseudoaglycon
equiv
dri
pyridin
ml
correspond
sulfonyl
chlorid
equiv
ad
reaction
mixtur
allow
stir
room
temperatur
h
afterward
methanol
ad
quench
reaction
solvent
evapor
crude
product
purifi
flash
chromatographi
use
gradient
elut
start
acetonitril
acetonitril
water
compound
stir
solut
mg
mmol
ch
cl
ml
et
n
ml
mmol
nbutylmercaptan
ml
mmol
ad
argon
atmospher
stir
h
room
temperatur
reaction
mixtur
evapor
crude
product
purifi
flash
chromatographi
hexan
aceton
give
desir
compound
mg
compound
stir
solut
mg
mmol
ch
cl
ml
et
n
ml
mmol
ad
cool
c
npropylmercaptan
ml
mmol
dissolv
ch
cl
ml
ad
dropwis
argon
atmospher
stir
h
reaction
mixtur
concentr
crude
product
purifi
flash
chromatographi
hexan
ethyl
acet
compound
stir
solut
teicoplanin
pseudoaglycon
mg
mmol
dri
dmf
ml
nethoxycarbonyl
bisalkylthio
maleimid
mg
mmol
et
n
ml
mmol
ad
argon
atmospher
stir
overnight
room
temperatur
reaction
mixtur
concentr
crude
product
purifi
flash
chromatographi
toluen
methanol
give
mg
yellow
powder
nmr
data
found
compound
compound
mg
mmol
react
propargylamin
work
accord
gener
method
b
crude
product
use
next
step
without
purif
see
compound
compound
compound
mg
mmol
azido
teicoplanin
pseudoaglycon
mg
mmol
react
accord
gener
method
c
give
mg
yellow
powder
nmr
data
found
tabl
compound
glycopeptid
prepar
reaction
compound
mg
mmol
azido
teicoplanin
pseudoaglycon
mg
mmol
accord
gener
method
c
purif
titl
compound
obtain
yellow
powder
mg
nmr
data
found
ml
mmol
ad
argon
atmospher
stir
h
room
temperatur
reaction
mixtur
evapor
crude
product
convert
nethoxycarbonyl
compound
work
accord
gener
method
yield
compound
use
step
without
purif
compound
compound
mg
mmol
triethylen
glycol
propargyl
ether
react
accord
gener
method
b
crude
product
purifi
flash
chromatographi
hexan
aceton
compound
stir
solut
mg
mmol
triethylen
glycol
propargyl
ether
ad
reaction
carri
accord
gener
method
b
reaction
work
use
crude
form
synthesi
final
product
compound
reaction
compound
mg
mmol
azido
teicoplanin
pseudoaglycon
mg
mmol
carri
accord
gener
method
c
give
mg
yellow
powder
nmr
data
found
tabl
compound
teicoplanin
pseudoaglycon
mg
mmol
ptoluenesulfonyl
chlorid
mg
mmol
allow
react
condit
describ
gener
method
e
crude
product
purifi
flash
chromatographi
give
mg
white
powder
nmr
data
found
tabl
compound
teicoplanin
pseudoaglycon
mg
mmol
biphenylsulfonyl
chlorid
mg
mmol
allow
react
condit
describ
gener
method
e
crude
product
purifi
flash
chromatographi
give
mg
white
powder
nmr
data
found
tabl
compound
teicoplanin
pseudoaglycon
mg
mmol
dansyl
chlorid
mg
mmol
allow
react
condit
describ
gener
method
e
crude
product
purifi
flash
chromatographi
give
mg
yellow
powder
nmr
data
found
tabl
detail
cpe
reduct
assay
influenza
viru
found
previou
public
viru
strain
infect
medium
consist
ultramdck
medium
lonza
supplement
sodium
bicarbon
mm
lglutamin
mgml
tosyl
phenylalanyl
chloromethyl
ketonetr
trypsin
day
semiconflu
cultur
madindarbi
canin
kidney
mdck
cell
plate
infect
influenza
viru
multipl
infect
moi
plaqu
form
unit
pfu
per
cell
three
day
incub
c
virusinduc
cpe
compound
cytotox
score
microscopi
data
confirm
formazanbas
mt
cell
viabil
assay
celltit
aq
ueou
one
solut
cell
prolifer
assay
promega
antivir
effect
express
compound
concentr
produc
inhibit
virusinduc
cpe
ec
compound
cytotox
express
compound
concentr
caus
minim
chang
cell
morpholog
mcc
cytotox
concentr
base
mt
cc
plasmid
lentivir
pseudoparticl
assay
describ
full
detail
elsewher
pcggagpol
gift
g
maerten
pqcxipacgfp
kind
gift
daeleman
two
pcagen
plasmid
ie
pcagen
backbon
kindli
provid
c
cepko
boston
via
addgen
plasmid
clone
ha
na
cdna
sequenc
four
plasmid
transfect
human
cell
produc
gfpexpress
lentivir
particl
two
day
transfect
supernat
collect
trypsin
ad
activ
influenza
protein
lentivir
transduct
mdck
cell
seed
cell
per
well
plate
incub
one
day
later
lentivir
particl
togeth
test
compound
three
day
incub
cell
trypsin
fixat
paraformaldehyd
submit
flow
cytometri
gfp
detect
use
bd
facscanto
ii
apparatu
human
embryon
lung
fibroblast
hel
cell
human
lung
carcinoma
cell
human
coronaviru
hcov
obtain
atcc
viru
infect
medium
contain
fetal
calf
serum
conduct
cpe
reduct
assay
confluent
hel
cell
cultur
plate
expos
moi
ccid
per
well
togeth
test
compound
day
incub
c
microscopi
perform
determin
ec
mcc
valu
definit
perform
qrtpcrbase
coronaviru
yield
assay
materi
nucleoproteinderiv
forward
primer
revers
primer
probe
standard
plasmid
sequenc
ngene
refer
compound
hcov
rna
synthesi
inhibitor
chemdiv
use
day
confluent
cell
plate
expos
compound
togeth
one
hour
infect
viru
inoculum
remov
cell
incub
c
presenc
compound
day
pi
supernat
frozen
c
qrtpcr
virion
lyse
treat
ml
sampl
ml
resuspens
buffer
ml
lysi
enhanc
cellsdirect
onestep
qrtpcr
kit
invitrogen
min
incub
c
next
quantif
cov
genom
copi
perform
onestep
qrtpcr
program
run
appli
biosystem
fast
instrument
consist
min
c
min
c
cycl
c
follow
c
ec
ec
valu
calcul
interpol
defin
compound
concentr
produc
respect
reduct
viral
rna
copi
number
compar
viru
control
receiv
compound
monitor
compound
cytotox
microscopi
done
mockinfect
cell
incub
compound
three
day
mcc
valu
defin
